Skip to content
CIVIC HERALD
HR 1672 · 119th Congress · HouseIn committee

Maintaining Investments in New Innovation Act

In plain language: Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Provisional: our plain-language summary, pending review.

Provisionalunreviewed: summary
People affected—not yet estimated
Fiscal magnitude—not yet estimated
Reach—
Your matchSign in →See how this matches your values.

How your members of Congress line up

Loading your members of Congress…

Timeline

How it moved.

  1. Feb 27, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Feb 27, 2025Introduced in House
  3. Feb 27, 2025Introduced in House

Sources & provenance

Congress.govrefreshed 15 days ago

Checking your session…